Autopsy report · NCT01940887
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy
Cause of deathNo reason given
Life of this trial
- Registered 8 months before it started.
- Ran for about 3 years 4 months before it stopped.
- 645 participants enrolled.
- Results were posted on the registry 3 years after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Ophthotech Corporation
- Sponsor type
- Industry
- Conditions
- Age-Related Macular Degeneration
- Interventions
- E10030; bevacizumab or aflibercept; E10030 sham injection
- Participants
- 645
- Sites
- 207
- Countries
- Argentina, Australia, Austria, Brazil, Canada, Colombia, Croatia, Czechia, Estonia, Finland, France, Germany and more
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.